{
  "ticker": "CU6",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973216",
  "id": "02973216",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250728",
  "time": "0942",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6fclzdgq5q2.pdf",
  "summary": "**Capital Raising Announcement Summary:**  \n- **Structure:** Institutional Placement  \n- **Amount Raised:** $203 million AUD  \n- **Issue Price:** $4.20 per share (2.2% premium to last close, 18.0% premium to 15-day VWAP).  \n- **Key Date:** Shares to trade on ASX from 1 August 2025.  \n- **Pro-Forma Cash Balance:** ~$288 million AUD (post-placement).  \n\n**Upcoming Catalysts/Milestones (Material to Valuation):**  \n- **Clinical Trials:**  \n  - **Co-PSMA trial readout (BCR):** Q3/Q4 2025.  \n  - **Phase 3 trials (AMPLIFY, CLARIFY):** Enrolment completion by Q4 2025 (AMPLIFY) and H1 2026 (CLARIFY).  \n  - **SECuRE (Phase 2) enrolment completion:** Q1 2026.  \n- **Regulatory:** NDA submission planning for 64Cu-SAR-bisPSMA.  \n- **Pipeline:** First-in-human trials for breast cancer (64/67Cu-SAR-trastuzumab) and diagnostic (64Cu-SAR-bisFAP) to commence H2 2026.  \n\n**Other Key Points:**  \n- Short interest ~10% of shares on issue pre-placement.  \n- Significant manufacturing/commercial prep for potential 64Cu-SAR-bisPSMA launch.  \n\n**Omitted:** Director commentary, operational details without direct financial/valuation impact.",
  "usage": {
    "prompt_tokens": 2623,
    "completion_tokens": 335,
    "total_tokens": 2958,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-27T23:58:30.140845"
}